ALMR | Ticker Profile - Titan Protect

ALMR

Alamar Biosciences, Inc.

Healthcare · Medical Devices · NMS

$20.54

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-27.17

Based on estimated future earnings — lower means cheaper

Rev Growth

+98.9%

Year-over-year revenue change

Profit Margin

-49.9%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+46% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.

https://alamarbio.com

Country: United States Employees: 222 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$27.20

24% below the year high

52W Low

$18.85

9% above the year low

Avg Volume

468,546

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.0%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.65

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

185.42

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.88

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.50

Like current ratio but excludes inventory — stricter test

Gross Margin

57.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-47.4%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$87M

Total revenue over the last 12 months

Net Income

$-43,485,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$35.00

Target Median

$30.00

Target Low

$27.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go